NEW DELHI, India India’s first COVID-19 vaccine got the approval for human trials from the country’s drug regulator, as number of coronavirus-related cases and deaths continues upward, a drug company announced. The vaccine, named COVAXIN, has been developed by Bharat Biotech compnay , in collaboration with the Indian Council of Medical Research and the National Institute of Virology (NIV). The indigenous, inactivated vaccine was developed from a SARS-CoV-2 strain, which was isolated by the NIV and transferred to the company’s BSL-3 High Containment facility located at Hyderabad city in southern India, Bharat Biotech said in a statement. “Our ongoing research and expertise in forecasting epidemics has enabled us to successfully manufacture a vaccine for the H1N1 pandemic, ” said Suchitra Ella, joint managing director of the company. The permission to initiate Phase I & II Human clinical trials came after the company submitted results generated from preclinica...
Comments
Post a Comment